Replenine-VF, 50 IU/mL human factor IX, a powder for solution.

Ülke: Malta

Dil: İngilizce

Kaynak: Medicines Authority

şimdi satın al

Indir Ürün özellikleri (SPC)
30-05-2024

Aktif bileşen:

FACTOR IX, HUMAN

Mevcut itibaren:

Bio Products Laboratory Limited

ATC kodu:

B02BD04

INN (International Adı):

FACTOR IX, HUMAN

Farmasötik formu:

POWDER FOR SOLUTION FOR INJECTION

Kompozisyon:

FACTOR IX, HUMAN 50 international unit(s)/millilitre

Reçete türü:

POM

Terapötik alanı:

ANTIHEMORRHAGICS

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2005-10-12

Bilgilendirme broşürü

                                1BDLBHF-FBGMFU*OGPSNBUJPOGPSUIF6TFS
REPLENINE
®
-VF 250 IU, 500 IU, 1000 IU 
POWDER FOR SOLUTION FOR INJECTION
)*()163*5:'"$503*9
1MFBTFSFBEBMMPGUIJTMFBGMFUDBSFGVMMZCFGPSFZPVTUBSUVTJOHUIJTNFEJDJOF

… ,FFQUIJTMFBGMFU:PVNBZOFFEUPSFBEJUBHBJO

… *GZPVIBWFBOZGVSUIFSRVFTUJPOTQMFBTFBTLZPVSEPDUPS

… 5IJTNFEJDJOFIBTCFFOQSFTDSJCFEGPSZPVQFSTPOBMMZ%POPUQBTTJUPOUPPUIFST*UNBZIBSNUIFNFWFOJGUIFJS
TZNQUPNTBSFUIFTBNFBTZPVST

… *GBOZPGUIFTJEFFGGFDUTHFUTTFSJPVTPSJGZPVOPUJDFBOZTJEFFGGFDUTOPUMJTUFEJOUIJTMFBGMFUQMFBTFUFMMZPVSEPDUPS
*OUIJTMFBGMFU

8IBU3FQMFOJOF7'JTBOEXIBUJUJTVTFEGPS

#FGPSFZPVVTF3FQMFOJOF7'

)PXUPVTF3FQMFOJOF7'

1PTTJCMFTJEFFGGFDUT

)PXUPTUPSF3FQMFOJOF7'

'VSUIFSJOGPSNBUJPO
8)"53&1-&/*/&7'*4"/%8)"5*5*464&%'03

3FQMFOJOF7'JTBIJHIQVSJUZGBDUPS*9GSPNIVNBOCMPPEQMBTNBPCUBJOFEGSPNTDSFFOFEEPOPST*UJTBXIJUFTUFSJMFQPXEFS
TVQQMJFEXJUITUFSJMFXBUFS 4UFSJMJTFE8BUFSGPS*OKFDUJPOT 

3FQMFOJOF7'JTHJWFOCZJOKFDUJPOJOUPBWFJO JOUSBWFOPVTMZ
BOEJTVTFEUPQSFWFOUBOEUSFBUCMFFEJOHJOQBUJFOUTXJUI
IBFNPQIJMJB# BOJOIFSJUFETIPSUBHFPGGBDUPS*9JOUIFCMPPE
:PVSEPDUPSXJMMFYQMBJOGVSUIFSXIZUIJTNFEJDJOFIBTCFFO
HJWFOUPZPV
#&'03&:0664&3&1-&/*/&7'
 %0/0564&UIJTNFEJDJOFJGZPV

… BSFBMMFSHJD IZQFSTFOTJUJWF
UPGBDUPS*9PSUPBOZPGUIFPUIFSJOHSFEJFOUT
_4FF4FDUJPO´'VSUIFSJOGPSNBUJPOµ_ 

5BLFTQFDJBMDBSFXJUI3FQMFOJOF7'JGZPV

… TVEEFOMZIBWFVOVTVBMCSVJTJOHBOEGFFMJOHWFSZVOXFMMXIJDINBZOFFETQFDJBMJTUNFEJDBMBUUFOUJPO

… IBWFIFBSUPSMJWFSEJTFBTFXIJDINBZOFFETQFDJBMJTUNFEJDBMBUUFOUJPO

… IBWFBSJTLPGCMPPEDMPUUJOH

… IBWFIBETVSHFSZ

… IBWFBIJHIMFWFMPGBOUJCPEJFTUPGBDUPS*9
:PVSEPDUPSNBZHJWFZPVBOBMUFSOBUJWFUSFBUNFOU)FTIFXJMMDIFDLUIFMFWFM
PGGBDUPS*9BOEBOUJCPEJFTJOZPVSCMPPECFGPSFBOEBGUFSUSFBUNFOU
                                
                                Belgenin tamamını okuyun
                                
                            

Ürün özellikleri

                                Page 1 of 11 
SUMMARY OF PRODUCT CHARACTERISTICS 
REPLENINE
®
-VF  
High Purity Factor IX 
 
1. 
NAME OF MEDICINAL PRODUCT 
 
 
Replenine
®
-VF, 50 IU/mL human factor IX, a powder for solution. 
 
2. 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Replenine-VF  is  a  high  purity  factor  IX.  This  product  is  prepared  from  plasma  from 
screened donors. Donors are selected from the USA. 
 
 
Replenine-VF  is  presented  as  a  sterile  powder  for  solution,  containing  nominally  250  IU, 
500  IU  or  1000  IU  human  coagulation  factor  IX  per  vial.  The  product  contains 
approximately 50 IU/mL when reconstituted with either 5 mL (250 IU vial), 10 mL (500 IU 
vial) or 20 mL (1000 IU vial) of Sterilised Water for Injections, Ph.Eur..  
 
One  mL  of  Replenine-VF  contains  approximately  100  IU  of  human  coagulation  factor  IX 
after reconstitution at half volume (see 6.6). 
 
The potency  (IU) is determined using the European Pharmacopoeia one stage clotting test. 
The specific activity of Replenine-VF is approximately 100 IU per mg of protein. 
 
For excipients, see section 6.1. 
 
3. 
PHARMACEUTICAL FORM 
 
Replenine-VF  is  a  powder  for  solution;  it  is  a  freeze-dried  concentrate  of  factor  IX  for 
reconstitution  with  Sterilised  Water  for  Injections,  Ph.Eur..    After  reconstitution  with  the 
supplied sterile water diluent, the product is administered intravenously.  
 
4. 
CLINICAL PARTICULARS 
 
4.1
 
THERAPEUTIC INDICATIONS 
 
Treatment and prophylaxis in patients with haemophilia B (congenital factor IX deficiency). 
 
4.2
 
POSOLOGY AND METHOD OF ADMINISTRATION 
 
Treatment  should  be  initiated  under  the  supervision  of  a  physic
                                
                                Belgenin tamamını okuyun